Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GALT | US
0.10
3.68%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
04/10/2024
2.82
2.75
3.16
2.73
Galectin Therapeutics Inc. a clinical stage biopharmaceutical company engages in the research and development of therapies for fibrotic cancer and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis as well as for the treatment of cancer. The company through its Galectin Sciences LLC which is a collaborative joint venture co-owned by SBH Sciences Inc. to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross Georgia.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
32.4%1 month
50.6%3 months
66.2%6 months
77.5%-
-
207.70
-1.14
3.38
-4.04
-
-
-
175.62M
175.62M
-
-
-
-
-3.73K
44.87
17.54
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.61
Range1M
0.76
Range3M
1.18
Rel. volume
3.17
Price X volume
1.15M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LFCR | LFCR | Drug Manufacturers-Specialty & Generic | 5.38 | 166.05M | 8.25% | 19.80 | 241.85% |
Zomedica Pharmaceuticals Corp | ZOM | Drug Manufacturers-Specialty & Generic | 0.138 | 137.72M | 5.83% | n/a | 1.10% |
CRDL | CRDL | Drug Manufacturers-Specialty & Generic | 1.97 | 137.67M | 2.07% | n/a | 1.07% |
Aceto Corporation | ACET | Drug Manufacturers-Specialty & Generic | 1.42 | 117.01M | -4.70% | n/a | 8.14% |
Veru Inc | VERU | Drug Manufacturers-Specialty & Generic | 0.7699 | 112.70M | 2.15% | n/a | 36.36% |
Karyopharm Therapeutics Inc | KPTI | Drug Manufacturers-Specialty & Generic | 0.8874 | 110.64M | 0.40% | n/a | -148.05% |
Assertio Therapeutics Inc | ASRT | Drug Manufacturers-Specialty & Generic | 1.14 | 108.68M | 1.79% | n/a | 30.76% |
OptiNose Inc | OPTN | Drug Manufacturers-Specialty & Generic | 0.7107 | 107.16M | 5.95% | n/a | -294.40% |
Relmada Therapeutics Inc | RLMD | Drug Manufacturers-Specialty & Generic | 3.48 | 105.01M | 2.35% | n/a | 0.00% |
Benitec Biopharma Limited | BNTC | Drug Manufacturers-Specialty & Generic | 9.48 | 95.62M | -7.06% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Unifi Inc | UFI | Textile Manufacturing | 6.74 | 123.04M | -2.46% | n/a | 52.56% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Culp Inc | CULP | Textile Manufacturing | 5.95 | 74.32M | -2.30% | n/a | 11.29% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.33 | 5.20M | 0.03% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.3899 | 3.55M | -0.01% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4859 | 2.44M | -9.19% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -4.04 | 17.21 | Cheaper |
Ent. to Revenue | - | 334.38 | - |
PE Ratio | - | 26.92 | - |
Price to Book | 207.70 | 12.15 | Expensive |
Dividend Yield | - | 2.77 | - |
Std. Deviation (3M) | 66.20 | 68.34 | Par |
Debt to Equity | -1.14 | -1.00 | Cheaper |
Debt to Assets | 3.38 | 0.48 | Expensive |
Market Cap | 175.62M | 5.31B | Emerging |